Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Clin Transl Gastroenterol ; 15(4): e00691, 2024 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-38334943

RESUMO

INTRODUCTION: The effects of genetic factors on pregnancy outcomes in chronic pancreatitis (CP) patients remain unclear. We evaluated the impacts of clinical features and mutations in main CP-susceptibility genes ( SPINK1 , PRSS1 , CTRC , and CFTR ) on pregnancy outcomes in Chinese CP patients. METHODS: This was a prospective cohort study with 14-year follow-up. The sample comprised female CP patients with documented pregnancy and known genetic backgrounds. Adverse pregnancy outcomes were compared between patients with and without gene mutations. Univariate and multivariate analyses were performed to determine the impact factors for adverse pregnancy outcomes. RESULTS: Totally, 160 female CP patients with a pregnancy history were enrolled; 59.4% of patients carried pathogenic mutations in CP-susceptibility genes. Adverse pregnancy outcomes occurred in 38 patients (23.8%); the prevalence of adverse outcomes was significantly higher in those harboring gene mutations than those without (30.5% vs 13.8%, P = 0.015). Notably, the rates of preterm delivery (12.6% vs 3.1%, P = 0.036) and abortion (17.9% vs 4.6%, P = 0.013) were remarkably higher in patients with gene mutations (especially SPINK1 mutations) than those without. In multivariate analyses, both CP-susceptibility gene mutations (odds ratio, 2.52; P = 0.033) and SPINK1 mutations (odds ratio, 2.60; P = 0.037) significantly increased the risk of adverse pregnancy outcomes. Acute pain attack during pregnancy was another risk factor for adverse pregnancy outcomes. DISCUSSION: Pathogenic mutations in CP-susceptibility genes, especially SPINK1 , were independently related to adverse pregnancy outcomes in CP patients. Significant attention should be paid to pregnant females harboring CP-susceptibility gene mutations (ClinicalTrials.gov: NCT06055595).


Assuntos
Quimotripsina , Regulador de Condutância Transmembrana em Fibrose Cística , Predisposição Genética para Doença , Mutação , Pancreatite Crônica , Complicações na Gravidez , Resultado da Gravidez , Inibidor da Tripsina Pancreática de Kazal , Tripsina , Humanos , Feminino , Gravidez , Adulto , Inibidor da Tripsina Pancreática de Kazal/genética , Pancreatite Crônica/genética , Pancreatite Crônica/complicações , Estudos Prospectivos , Tripsina/genética , Complicações na Gravidez/genética , Regulador de Condutância Transmembrana em Fibrose Cística/genética , China/epidemiologia , Nascimento Prematuro/epidemiologia , Nascimento Prematuro/genética , Adulto Jovem , Seguimentos , Fatores de Risco , Aborto Espontâneo/genética , Aborto Espontâneo/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA